Back

Effects of icosapent ethyl on residual cardiovascular risk according to predicted baseline risk: results from REDUCE-IT

27 August 2023 (11:05 - 11:15)
Organised by: Logo
Congress Presentation Part of: What's new in lipid lowering? Drug therapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Pascal Burger

University Medical Center Utrecht, Utrecht (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: a meta-analysis of 59 trials
Doctor P. Burger (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
Doctor A. Khera (Boston, US)
Abstract Slides Video
Presentation thumbnail
Attainment of LDL-cholesterol goals in patients with previous myocardial infarction: a real-world cross-sectional analysis
Mr D. Gomes (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Lipoprotein(a) is not a causal factor for the development of diabetes - a two-sample Mendelian randomization study.
Associate Professor T. Osadnik (Zabrze, PL)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): Implications for the OCEAN(a)-Outcomes trial population
Doctor B. Weber (Dallas, US)
Abstract Slides Video

Access the full session

Session thumbnail
What's new in lipid lowering?
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Managing a patient with residual risk: applying recent evidence with EPA to practice
thumbnail
Congress Presentation
Understanding the clinical benefit of icosapent ethyl: insights from REDUCE-IT
thumbnail
Congress Session
What's new in lipid lowering?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources